Accessible Requires Authentication Published by De Gruyter June 6, 2017

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

Peter B Gilbert, Michal Juraska, Allan C. deCamp, Shelly Karuna, Srilatha Edupuganti, Nyaradzo Mgodi, Deborah J Donnell, Carter Bentley, Nirupama Sista, Philip Andrew, Abby Isaacs, Yunda Huang, Lily Zhang, Edmund Capparelli, Nidhi Kochar, Jing Wang, Susan H Eshleman, Kenneth H Mayer, Craig A Magaret, John Hural, James G Kublin, Glenda Gray, David C Montefiori, Margarita M Gomez, David N Burns, Julie McElrath, Julie Ledgerwood, Barney S Graham, John R Mascola, Myron Cohen and Lawrence Corey



Anti-HIV-1 broadly neutralizing antibodies (bnAbs) have been developed as potential agents for prevention of HIV-1 infection. The HIV Vaccine Trials Network and the HIV Prevention Trials Network are conducting the Antibody Mediated Prevention (AMP) trials to assess whether, and how, intravenous infusion of the anti-CD4 binding site bnAb, VRC01, prevents HIV-1 infection. These are the first test-of-concept studies to assess HIV-1 bnAb prevention efficacy in humans.


The AMP trials are two parallel phase 2b HIV-1 prevention efficacy trials conducted in two cohorts: 2700 HIV-uninfected men and transgender persons who have sex with men in the United States, Peru, Brazil, and Switzerland; and 1500 HIV-uninfected sexually active women in seven countries in sub-Saharan Africa. Participants are randomized 1:1:1 to receive an intravenous infusion of 10 mg/kg VRC01, 30 mg/kg VRC01, or a control preparation every 8 weeks for a total of 10 infusions. Each trial is designed (1) to assess overall prevention efficacy (PE) pooled over the two VRC01 dose groups vs. control and (2) to assess VRC01 dose and laboratory markers as correlates of protection (CoPs) against overall and genotype- and phenotype-specific infection.


Each AMP trial is designed to have 90 % power to detect PE > 0 % if PE is ≥ 60 %. The AMP trials are also designed to identify VRC01 properties (i. e., concentration and effector functions) that correlate with protection and to provide insight into mechanistic CoPs. CoPs are assessed using data from breakthrough HIV-1 infections, including genetic sequences and sensitivities to VRC01-mediated neutralization and Fc effector functions.


The AMP trials test whether VRC01 can prevent HIV-1 infection in two study populations. If affirmative, they will provide information for estimating the optimal dosage of VRC01 (or subsequent derivatives) and identify threshold levels of neutralization and Fc effector functions associated with high-level protection, setting a benchmark for future vaccine evaluation and constituting a bridge to other bnAb approaches for HIV-1 prevention.

Funding statement: Funding sources: This work was supported by the National Institute of Allergy and Infectious Disease at the National Institutes of Health [2 R37 AI054165-11 to P.B.G., UM1 AI068635 to P.B.G., UM1 AI068617 to D.J.D., UM1 AI068619 to M.C., UM1 AI068618 to J.M., UM1 AI068614 to L.C.]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.


The authors would like to thank the protocol team of the AMP trials and the many groups and individuals dedicated to planning and conducting these trials, as well as the AMP trial participants. The authors also thank Lindsay Carpp for technical writing.

  1. Conflict of interest statement: All authors have no potential conflicts of interest to declare.

  2. Meetings where this research was presented: P.B.G. presented an early version of this research at the Passive Immunization Trials to Inform Vaccine Design Workshop at the Global HIV Vaccine Enterprise in August of 2014 in New York City, with talk title “Statistical issues in assessing treatment efficacy and correlates of protection in monoclonal antibody efficacy trials.”


ADCC, antibody-dependent cellular cytotoxicity; ADCP, antibody-dependent cellular phagocytosis; ADCVI, antibody-dependent cell-mediated viral inhibition; AMP, Antibody Mediated Prevention; ARVs, antiretroviral drugs; bnAb, broadly neutralizing antibody; CoP, correlate of protection; DSMB, Data Safety and Monitoring Board; IC50, 50 % inhibitory concentration; ITT, intention-to-treat; IV, intravenous; mAb, monoclonal antibody; MITT, modified intention-to-treat; MSM, men who have sex with men; NHP, non-human primate; PE, prevention efficacy; PEP, post-exposure prophylaxis; PK, pharmacokinetic; PrEP, pre-exposure prophylaxis; RSV, respiratory syncytial virus; TG, transgender persons; tMLE, targeted minimum loss based estimation; VRC, Vaccine Research Center.


Abdool, K.Q., S.S. Abdool Karim, J.A. Frohlich, A.C. Grobler, C. Baxter, L.E. Mansoor, A.B. Kharsany, S. Sibeko, K.P. Mlisana, Z. Omar, T.N. Gengiah, S. Maarschalk, N. Arulappan, M. Mlotshwa, L. Morris, and D. Taylor. 2010. “Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women.” Science 329 (5996): 1168–1174. Search in Google Scholar

AIDSinfo. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents: Limitations to Treatment Safety and Efficacy: Adverse Effects of Antiretroviral Agents. 2014 Last Modified May 1, 2014. Accessed Feburary 2, 2015, Search in Google Scholar

Asmal, M., Y. Sun, S. Lane, W. Yeh, S.D. Schmidt, J.R. Mascola, and N.L. Letvin. 2011. “Antibody-Dependent Cell-Mediated Viral Inhibition Emerges after Simian Immunodeficiency Virus Sivmac251 Infection of Rhesus Monkeys Coincident with Gp140-Binding Antibodies and Is Effective against Neutralization-Resistant Viruses.” Journal of Virology 85 (11): 5465–5475. Search in Google Scholar

Baba, T.W., V. Liska, R. Hofmann-Lehmann, J. Vlasak, W. Xu, S. Ayehunie, L.A. Cavacini, M.R. Posner, H. Katinger, G. Stiegler, B.J. Bernacky, T.A. Rizvi, R. Schmidt, L.R. Hill, M.E. Keeling, Y. Lu, J.E. Wright, T.C. Chou, and R.M. Ruprecht. 2000. “Human Neutralizing Monoclonal Antibodies of the Igg1 Subtype Protect against Mucosal Simian-Human Immunodeficiency Virus Infection.” Nature Medicine 6 (2): 200–206. Search in Google Scholar

Baeten, J.M., D. Donnell, P. Ndase, N.R. Mugo, J.D. Campbell, J. Wangisi, J.W. Tappero, E.A. Bukusi, C.R. Cohen, E. Katabira, A. Ronald, E. Tumwesigye, E. Were, K.H. Fife, J. Kiarie, C. Farquhar, G. John-Stewart, A. Kakia, J. Odoyo, A. Mucunguzi, E. Nakku-Joloba, R. Twesigye, K. Ngure, C. Apaka, H. Tamooh, F. Gabona, A. Mujugira, D. Panteleef, K.K. Thomas, L. Kidoguchi, M. Krows, J. Revall, S. Morrison, H. Haugen, M. Emmanuel-Ogier, L. Ondrejcek, R.W. Coombs, L. Frenkel, C. Hendrix, N.N. Bumpus, D. Bangsberg, J.E. Haberer, W.S. Stevens, J.R. Lingappa, and C. Celum. 2012. “Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women.” New England Journal of Medicine 367 (5): 399–410. Search in Google Scholar

Binley, J.M., E.A. Lybarger, E.T. Crooks, M.S. Seaman, E. Gray, K.L. Davis, J.M. Decker, D. Wycuff, L. Harris, N. Hawkins, B. Wood, C. Nathe, D. Richman, G.D. Tomaras, F. Bibollet-Ruche, J.E. Robinson, L. Morris, G.M. Shaw, D.C. Montefiori, and J.R. Mascola. 2008. “Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C.” Journal of Virology 82 (23): 11651–11668. Search in Google Scholar

Burton, D.R., R.L. Stanfield, and I.A. Wilson. 2005. “Antibody Vs. HIV in a Clash of Evolutionary Titans.” Proceedings of the National Academy of Sciences 102 (42): 14943–14948. Search in Google Scholar

Caskey, M., F. Klein, J.C. Lorenzi, M.S. Seaman, A.P. West, Jr., N. Buckley, G. Kremer, L. Nogueira, M. Braunschweig, J.F. Scheid, J.A. Horwitz, I. Shimeliovich, S. Ben-Avraham, M. Witmer-Pack, M. Platten, C. Lehmann, L.A. Burke, T. Hawthorne, R.J. Gorelick, B.D. Walker, T. Keler, R.M. Gulick, G. Fatkenheuer, S.J. Schlesinger, and M.C. Nussenzweig. 2015. “Viraemia Suppressed in HIV-1-Infected Humans by Broadly Neutralizing Antibody 3BNC117.” Nature 522 (7557): 487–491. Search in Google Scholar

Celum, C., A. Wald, J. Hughes, J. Sanchez, S. Reid, S. Delany-Moretlwe, F. Cowan, M. Casapia, A. Ortiz, J. Fuchs, S. Buchbinder, B. Koblin, S. Zwerski, S. Rose, J. Wang, and L. Corey. 2008. “Effect of Aciclovir on HIV-1 Acquisition in Herpes Simplex Virus 2 Seropositive Women and Men Who Have Sex with Men: A Randomised, Double-Blind, Placebo-Controlled Trial.” Lancet 371 (9630): 2109–2119. Search in Google Scholar

Centers for Disease Control. 1981. “Pneumocystis Pneumonia–Los Angeles.” Morbidity and Mortality Weekly Report 30 (21): 250–252. Search in Google Scholar

Centers for Disease Control and Prevention. “Estimated HIV Incidence in the United States, 2007-2010. 2012 Last Modified 12, 2012 Accessed 07, 08 Search in Google Scholar

Centers for Disease Control and Prevention. Diagnoses of HIV Infection in the United States and Dependent Areas, 2013. 2015 Last Modified Feburary 23, 2015 Accessed 07, 08, Search in Google Scholar

Cohen, M.S., Y.Q. Chen, M. McCauley, T. Gamble, M.C. Hosseinipour, N. Kumarasamy, J.G. Hakin, J. Kumwenda, B. Grinsztejn, J.H. Pilotto, S.V. Godbole, S. Mehendale, S. Chariyalertsak, B.R. Santos, K.H. Mayer, I.F. Hoffman, S.H. Eshleman, E. Piwowar-Manning, L. Wang, J. Makhema, L.A. Mills, G. de Bruyn, I. Sanne, J. Eron, J. Gallant, D. Havlir, S. Swindells, H. Ribaudo, V. Elharrar, D. Burns, T.E. Taha, K. Nielsen-Saines, D. Celentano, M. Essex, and T.R. Fleming. 2011. “Prevention of HIV-1 Infection with Early Antiretroviral Therapy.” New England Journal of Medicine 365 (6): 493–505. Search in Google Scholar

Cohen, M.S., Y.Q. Chen, M. McCauley, T. Gamble, M.C. Hosseinipour, N. Kumarasamy, J.G. Hakim, J. Kumwenda, B. Grinsztejn, J.H.S. Pilotto, S.V. Godbole, S. Chariyalertsak, B.R. Santos, K.H. Mayer, I.F. Hoffman, S.H. Eshleman, E. Piwowar-Manning, L. Cottle, X.C. Zhang, J. Makhema, L.A. Mills, R. Panchia, S. Faesen, J. Eron, J. Gallant, D. Havlir, S. Swindells, V. Elharrar, D. Burns, T.E. Taha, K. Nielsen-Saines, D.D. Celentano, M. Essex, S.E. Hudelson, A.D. Redd, and T.R. Fleming. 2016. “Antiretroviral Therapy for the Prevention of HIV-1 Transmission.” New England Journal of Medicine 375: 830–839. Search in Google Scholar

Corti, D., J.P. Langedijk, A. Hinz, M.S. Seaman, F. Vanzetta, B.M. Fernandez-Rodriguez, C. Silacci, D. Pinna, D. Jarrossay, S. Balla-Jhagjhoorsingh, B. Willems, M.J. Zekveld, H. Dreja, E. O'Sullivan, C. Pade, C. Orkin, S.A. Jeffs, D.C. Montefiori, D. Davis, W. Weissenhorn, A. McKnight, J.L. Heeney, F. Sallusto, Q.J. Sattentau, R.A. Weiss, and A. Lanzavecchia. 2010. “Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals.” Plos One 5 (1): 8805. Search in Google Scholar

Cottrell, M.L., K.H. Yang, H.M. Prince, C. Sykes, N. White, S. Malone, E.S. Dellon, R.D. Madanick, N.J. Shaheen, M.G. Hudgens, J. Wulff, K.B. Patterson, and J.A. Nelson. 2016. “A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis against HIV in Men and Women Using Tenofovir Disoproxil Fumarate with or without Emtricitabine.” J Infect Dis 214 (1): 55–64. Search in Google Scholar

Crooks, G.E., G. Hon, J.M. Chandonia, and S.E. Brenner. 2004. “Weblogo: A Sequence Logo Generator.” Genome Research 14 (6): 1188–1190. Search in Google Scholar

Edlefsen, P.T., C.A. Magaret, A. Poon, F. Matsen IV, M. Rolland, L.A. Eller, S. Tovanabutra, D. Chopera, P. Labuschagne, C. Warth, T. Holzman, R. Rossenkhan, M.-R. Abrahams, M. Logan, C. Anthony, D. Botha, D. Mattern, S. Nitayaphan, K. Rono, A. Sekiziyivu, N. Ndabambi, S. Travers, N. Michael, C. Williamson, M. Robb, and P.B. Gilbert. (2016).Systematic Evaluation of HIV Infection Time and Founder Inferences Using SGA and Illumina Sequences. KeyStone Symposia on Molecular and Cellular Biology HIV Vaccines (X8), Olympic Valley, CA. Search in Google Scholar

Ellenberg, S.S., T.R. Fleming, and D.L. DeMets. 2002. Data Monitoring Committees in Clinical Trials: A Practical Perspective. West Sussex, England: Wiley. Search in Google Scholar

Emanuel, E.J., and F.G. Miller. 2001. “The Ethics of Placebo-Controlled Trials–A Middle Ground.” New England Journal of Medicine 345 (12): 915–919. Search in Google Scholar

Emanuel, E.J., D. Wendler, and C. Grady. 2000. “What Makes Clinical Research Ethical?” Journal of the American Medical Association 283 (20): 2701–2711. Search in Google Scholar

Falkowska, E., A. Ramos, Y. Feng, T. Zhou, S. Moquin, L.M. Walker, X. Wu, M.S. Seaman, T. Wrin, P.D. Kwong, R.T. Wyatt, J.R. Mascola, P. Poignard, and D.R. Burton. 2012. “PGV04, an HIV-1 Gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4.” Journal of Virology 86 (8): 4394–4403. Search in Google Scholar

Fauci, A.S., G.K. Folkers, and H.D. Marston. 2014. “Ending the Global HIV/AIDS Pandemic: The Critical Role of an HIV Vaccine.” Clinical Infectious Diseases 59 (Suppl 2): 80–4. Search in Google Scholar

Fleming, T.R., and B.A. Richardson. 2004. “Some Design Issues in Trials of Microbicides for the Prevention of HIV Infection.” Journal of Infectious Diseases 190 (4): 666–674. Search in Google Scholar

Florese, R.H., T. Demberg, P. Xiao, L. Kuller, K. Larsen, L.E. Summers, D. Venzon, A. Cafaro, B. Ensoli, and M. Robert-Guroff. 2009. “Contribution of Nonneutralizing Vaccine-Elicited Antibody Activities to Improved Protective Efficacy in Rhesus Macaques Immunized with Tat/Env Compared with Multigenic Vaccines.” Journal of Immunology 182 (6): 3718–3727. Search in Google Scholar

Follmann, D. 2006. “Augmented Designs to Assess Immune Response in Vaccine Trials.” Biometrics 62 (4): 1161–1169. Search in Google Scholar

Fong, Y., C. Di, and S. Permar. 2015. “Change Point Testing in Logistic Regression Models with Interaction Term.” Statistics in Medicine 34 (9): 1483–1494. Search in Google Scholar

Forthal, D.N., G. Landucci, T.B. Phan, and J. Becerra. 2005. “Interactions between Natural Killer Cells and Antibody Fc Result in Enhanced Antibody Neutralization of Human Immunodeficiency Virus Type 1.” Journal of Virology 79 (4): 2042–2049. Search in Google Scholar

Freidlin, B., E.L. Korn, and R. Gray. 2010. “A General Inefficacy Interim Monitoring Rule for Randomized Clinical Trials.” Clinical Trials 7 (3): 197–208. Search in Google Scholar

Gabriel, E.E., and P.B. Gilbert. 2014. “Evaluating Principal Surrogate Endpoints with Time-To-Event Data Accounting for Time-Varying Treatment Efficacy.” Biostatistics 15 (2): 251–265. Search in Google Scholar

Georgiev, I.S., J.M. Gordon, T. Zhou, and P.D. Kwong. 2013. “Elicitation of HIV-1-Neutralizing Antibodies against the CD4-Binding Site.” Current Opinion in HIV and AIDS 8 (5): 382–392. Search in Google Scholar

Gilbert, P., M. Wang, T. Wrin, C. Petropoulos, M. Gurwith, F. Sinangil, P. D'Souza, I.R. Rodriguez-Chavez, A. DeCamp, M. Giganti, P.W. Berman, S.G. Self, and D.C. Montefiori. 2010. “Magnitude and Breadth of a Nonprotective Neutralizing Antibody Response in an Efficacy Trial of a Candidate HIV-1 Gp120 Vaccine.” Journal of Infectious Diseases 202 (4): 595–605. Search in Google Scholar

Gilbert, P.B. 2010. “Some Design Issues in Phase 2B Vs Phase 3 Prevention Trials for Testing Efficacy of Products or Concepts.” Statistics in Medicine 29 (10): 1061–1071. Search in Google Scholar

Gilbert, P.B., E.E. Gabriel, X. Miao, X. Li, S.C. Su, J. Parrino, and I.S. Chan. 2014. “Fold Rise in Antibody Titers by Measured by Glycoprotein-Based Enzyme-Linked Immunosorbent Assay Is an Excellent Correlate of Protection for a Herpes Zoster Vaccine, Demonstrated via the Vaccine Efficacy Curve.” Journal of Infectious Diseases 210 (10): 1573–1581. Search in Google Scholar

Gilbert, P.B., D. Grove, E. Gabriel, Y. Huang, G. Gray, S.M. Hammer, S.P. Buchbinder, J. Kublin, L. Corey, and S.G. Self. 2011. “A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens.” Statistical Communications in Infectious Diseases 3 (1): Article 4. DOI:10.2202/1948-4690.1037. Search in Google Scholar

Gilbert, P.B., and M.G. Hudgens. 2008. “Evaluating Candidate Principal Surrogate Endpoints.” Biometrics 64 (4): 1146–1154. Search in Google Scholar

Gilbert, P.B., H.E. Janes, and Y. Huang. 2016. “Power/Sample Size Calculations for Assessing Correlates of Risk in Clinical Efficacy Trials.” Stat Med 35 (21): 3745–3759. Search in Google Scholar

Graham, B.S., and D.M. Ambrosino. 2015. “History of Passive Antibody Administration for Prevention and Treatment of Infectious Diseases.” Curr Opin HIV AIDS 10 (3): 129–134. Search in Google Scholar

Grant, R.M., J.R. Lama, P.L. Anderson, V. McMahan, A.Y. Liu, L. Vargas, P. Goicochea, M. Casapia, J.V. Guanira-Carranza, M.E. Ramirez-Cardich, O. Montoya-Herrera, T. Fernandez, V.G. Veloso, S.P. Buchbinder, S. Chariyalertsak, M. Schechter, L.G. Bekker, K.H. Mayer, E.G. Kallas, K.R. Amico, K. Mulligan, L.R. Bushman, R.J. Hance, C. Ganoza, P. Defechereux, B. Postle, F. Wang, J.J. McConnell, J.H. Zheng, J. Lee, J.F. Rooney, H.S. Jaffe, A.I. Martinez, D.N. Burns, and D.V. Glidden. 2010. “Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men.” New England Journal of Medicine 363 (27): 2587–2599. Search in Google Scholar

Gray, E.S., M.C. Madiga, T. Hermanus, P.L. Moore, C.K. Wibmer, N.L. Tumba, L. Werner, K. Mlisana, S. Sibeko, C. Williamson, S.S. Abdool Karim, and L. Morris. 2011a. “The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection.” Journal of Virology 85 (10): 4828–4840. Search in Google Scholar

Gray, E.S., N. Taylor, D. Wycuff, P.L. Moore, G.D. Tomaras, C.K. Wibmer, A. Puren, A. DeCamp, P.B. Gilbert, B. Wood, D.C. Montefiori, J.M. Binley, G.M. Shaw, B.F. Haynes, J.R. Mascola, and L. Morris. 2009. “Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors.” Journal of Virology 83 (17): 8925–8937. Search in Google Scholar

Gray, G.E., M. Allen, Z. Moodie, G. Churchyard, L.G. Bekker, M. Nchabeleng, K. Mlisana, B. Metch, G. de Bruyn, M.H. Latka, S. Roux, M. Mathebula, N. Maicker, C. Ducar, D.K. Carter, A. Puren, N. Eaton, M.J. McElrath, M. Robertson, L. Corey, and J.G. Kublin. 2011b. “Safety and Efficacy of the HVTN 503/Phambili Study of A Clade-B-Based HIV-1 Vaccine in South Africa: A Double-Blind, Randomised, Placebo-Controlled Test-Of-Concept Phase 2b Study.” Lancet Infectious Diseases 11 (7): 507–515. Search in Google Scholar

Gray, G.E., Z. Moodie, B. Metch, P.B. Gilbert, L.G. Bekker, G. Churchyard, M. Nchabeleng, K. Mlisana, F. Laher, S. Roux, K. Mngadi, C. Innes, M. Mathebula, M. Allen, M.J. McElrath, M. Robertson, J. Kublin, and L. Corey. 2014. “Recombinant Adenovirus Type 5 HIV Gag/Pol/Nef Vaccine in South Africa: Unblinded, Long-Term Follow-Up of the Phase 2b HVTN 503/Phambili Study.” Lancet Infect.Dis. 14 (5): 388–396. Search in Google Scholar

Hall, H.I., R. Song, P. Rhodes, J. Prejean, Q. An, L.M. Lee, J. Karon, R. Brookmeyer, E.H. Kaplan, M.T. McKenna, and R.S. Janssen. 2008. “Estimation of HIV Incidence in the United States.” Journal of the American Medical Association 300 (5): 520–529. Search in Google Scholar

Hammer, S.M., M.E. Sobieszczyk, H. Janes, S.T. Karuna, M.J. Mulligan, D. Grove, B.A. Koblin, S.P. Buchbinder, M.C. Keefer, G.D. Tomaras, N. Frahm, J. Hural, C. Anude, B.S. Graham, M.E. Enama, E. Adams, E. DeJesus, R.M. Novak, I. Frank, C. Bentley, S. Ramirez, R. Fu, R.A. Koup, J.R. Mascola, G.J. Nabel, D.C. Montefiori, J. Kublin, M.J. McElrath, L. Corey, and P.B. Gilbert. 2013. “Efficacy Trial of a DNA/Rad5 HIV-1 Preventive Vaccine.” New England Journal of Medicine 369 (22): 2083–2092. Search in Google Scholar

Haynes, B.F., P.B. Gilbert, M.J. McElrath, S. Zolla-Pazner, G.D. Tomaras, S.M. Alam, D.T. Evans, D.C. Montefiori, C. Karnasuta, R. Sutthent, H.X. Liao, A.L. DeVico, G.K. Lewis, C. Williams, A. Pinter, Y. Fong, H. Janes, A. DeCamp, Y. Huang, M. Rao, E. Billings, N. Karasavvas, M.L. Robb, V. Ngauy, M.S. de Souza, R. Paris, G. Ferrari, R.T. Bailer, K.A. Soderberg, C. Andrews, P.W. Berman, N. Frahm, S.C. De Rosa, M.D. Alpert, N.L. Yates, X. Shen, R.A. Koup, P. Pitisuttithum, J. Kaewkungwal, S. Nitayaphan, S. Rerks-Ngarm, N.L. Michael, and J.H. Kim. 2012. “Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial.” New England Journal of Medicine 366 (14): 1275–1286. Search in Google Scholar

Hessell, A.J., E.G. Rakasz, P. Poignard, L. Hangartner, G. Landucci, D.N. Forthal, W.C. Koff, D.I. Watkins, and D.R. Burton. 2009. “Broadly Neutralizing Human Anti-Hiv Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers.” Plos Pathogens 5 (5): 1000433. Search in Google Scholar

Hofmann-Lehmann, R., J. Vlasak, R.A. Rasmussen, S. Jiang, P.L. Li, T.W. Baba, D.C. Montefiori, B.J. Bernacky, T.A. Rizvi, R. Schmidt, L.R. Hill, M.E. Keeling, H. Katinger, G. Stiegler, L.A. Cavacini, M.R. Posner, and R.M. Ruprecht. 2002. “Postnatal Pre- and Postexposure Passive Immunization Strategies: Protection of Neonatal Macaques against Oral Simian-Human Immunodeficiency Virus Challenge.” Journal of Medical Primatology 31 (3): 109–119. Search in Google Scholar

Huang, J., G. Ofek, L. Laub, M.K. Louder, N.A. Doria-Rose, N.S. Longo, H. Imamichi, R.T. Bailer, B. Chakrabarti, S.K. Sharma, S.M. Alam, T. Wang, Y. Yang, B. Zhang, S.A. Migueles, R. Wyatt, B.F. Haynes, P.D. Kwong, J.R. Mascola, and M. Connors. 2012. “Broad and Potent Neutralization of HIV-1 by a Gp41-Specific Human Antibody.” Nature 491 (7424): 406–412. Search in Google Scholar

Huang, Y., P.B. Gilbert, D.C. Montefiori, and S.G. Self. 2009. “Simultaneous Evaluation of the Magnitude and Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine Development.” Statistics in Biopharmaceutical Research 1 (1): 81–91. Search in Google Scholar

Huang, Y., P.B. Gilbert, and J. Wolfson. 2013. “Design and Estimation for Evaluating Principal Surrogate Markers in Vaccine Trials.” Biometrics 69 (2): 301–309. Search in Google Scholar

Janes, H., P. Gilbert, S. Buchbinder, J. Kublin, M.E. Sobieszczyk, and S.M. Hammer. 2013. “In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Nonvaccine Prevention Modalities.” AIDS Research and Human Retroviruses 29 (11): 1513–1523. Search in Google Scholar

Kalbfleisch, J., and R. Prentice. 2002. The Statistical Analysis of Failure Time Data., 2nd. Hoboken, NJ: John Wiley & Sons, Inc. Search in Google Scholar

Ko, S.Y., A. Pegu, R.S. Rudicell, Z.Y. Yang, M.G. Joyce, X. Chen, K. Wang, S. Bao, T.D. Kraemer, T. Rath, M. Zeng, S.D. Schmidt, J.P. Todd, S.R. Penzak, K.O. Saunders, M.C. Nason, A.T. Haase, S.S. Rao, R.S. Blumberg, J.R. Mascola, and G.J. Nabel. 2014. “Enhanced Neonatal Fc Receptor Function Improves Protection against Primate SHIV Infection.” Nature 514 (7524): 642–645. Search in Google Scholar

Koblin, B.A., K.H. Mayer, S.H. Eshleman, L. Wang, S. Mannheimer, C. Del Rio, S. Shoptaw, M. Magnus, S. Buchbinder, L. Wilton, T.Y. Liu, V. Cummings, E. Piwowar-Manning, S.D. Fields, S. Griffith, V. Elharrar, and D. Wheeler. 2013. “Correlates of HIV Acquisition in a Cohort of Black Men Who Have Sex with Men in the United States: HIV Prevention Trials Network (HPTN) 061.” Plos One 8 (7): 70413. Search in Google Scholar

Kong, L., J.H. Lee, K.J. Doores, C.D. Murin, J.P. Julien, R. McBride, Y. Liu, A. Marozsan, A. Cupo, P.J. Klasse, S. Hoffenberg, M. Caulfield, C.R. King, Y. Hua, K.M. Le, R. Khayat, M.C. Deller, T. Clayton, H. Tien, T. Feizi, R.W. Sanders, J.C. Paulson, J.P. Moore, R.L. Stanfield, D.R. Burton, A.B. Ward, and I.A. Wilson. 2013. “Supersite of Immune Vulnerability on the Glycosylated Face of HIV-1 Envelope Glycoprotein Gp120.” Nature Structural & Molecular Biology 20 (7): 796–803. Search in Google Scholar

Kwong, P.D., and J.R. Mascola. 2012. “Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies.” Immunity 37 (3): 412–425. Search in Google Scholar

Ledgerwood, J.E., E.E. Coates, G. Yamshchikov, J.G. Saunders, L. Holman, M.E. Enama, A. DeZure, R.M. Lynch, I. Gordon, S. Plummer, C.S. Hendel, A. Pegu, M. Conan-Cibotti, S. Sitar, R.T. Bailer, S. Narpala, A. McDermott, M. Louder, S. O'Dell, S. Mohan, J.P. Pandey, R.M. Schwartz, Z. Hu, R.A. Koup, E. Capparelli, J.R. Mascola, and B.S. Graham. 2015. “Safety, Pharmacokinetics and Neutralization of the Broadly Neutralizing HIV-1 Human Monoclonal Antibody VRC01 in Healthy Adults.” Clinical & Experimental Immunology 182 (3): 289–301. Search in Google Scholar

Li, Y., S.A. Migueles, B. Welcher, K. Svehla, A. Phogat, M.K. Louder, X. Wu, G.M. Shaw, M. Connors, R.T. Wyatt, and J.R. Mascola. 2007. “Broad HIV-1 Neutralization Mediated by CD4-Binding Site Antibodies.” Nature Medicine 13 (9): 1032–1034. Search in Google Scholar

Lynch, R.M., E. Boritz, E.E. Coates, A. DeZure, P. Madden, P. Costner, M.E. Enama, S. Plummer, L. Holman, C.S. Hendel, I. Gordon, J. Casazza, M. Conan-Cibotti, S.A. Migueles, R. Tressler, R.T. Bailer, A. McDermott, S. Narpala, S. O'Dell, G. Wolf, J.D. Lifson, B.A. Freemire, R.J. Gorelick, J.P. Pandey, S. Mohan, N. Chomont, R. Fromentin, T.W. Chun, A.S. Fauci, R.M. Schwartz, R.A. Koup, D.C. Douek, Z. Hu, E. Capparelli, B.S. Graham, J.R. Mascola, and J.E. Ledgerwood. 2015. “Virologic Effects of Broadly Neutralizing Antibody VRC01 Administration during Chronic HIV-1 Infection.” Science Translational Medicine 7 (319): 319ra206. Search in Google Scholar

Marrazzo, J.M., G. Ramjee, B.A. Richardson, K. Gomez, N. Mgodi, G. Nair, T. Palanee, C. Nakabiito, J.Y. Dai, S. Ganesh, B. Mkhize, M. Taljaard, U.M. Parikh, J. Piper, B. Masse, C. Grossman, J. Rooney, J.L. Schwartz, H. Watts, M.A. Marzinke, S.L. Hillier, I.M. McGowan, and Z.M. Chirenje. 2015. “Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women.” New England Journal of Medicine 372: 509–518. Search in Google Scholar

Mayer, K., K. Seaton, Y. Huang, N. Grunenberg, J. Hural, J. Ledgerwood, R. Bailer, R. Koup, M. Allen, B. Graham, and the HVTN 104 protocol team. 2016. Clinical Safety and Pharmacokinetics of IV and SC VRC01, a Broadly Neutralizing Mab. Boston: CROI. Search in Google Scholar

McCormack, S., D.T. Dunn, M. Desai, D.I. Dolling, M. Gafos, R. Gilson, A.K. Sullivan, A. Clarke, I. Reeves, G. Schembri, N. Mackie, C. Bowman, C.J. Lacey, V. Apea, M. Brady, J. Fox, S. Taylor, S. Antonucci, S.H. Khoo, J. Rooney, A. Nardone, M. Fisher, A. McOwan, A.N. Phillips, A.M. Johnson, B. Gazzard, and O.N. Gill. 2016. “Pre-Exposure Prophylaxis to Prevent the Acquisition of HIV-1 Infection (PROUD): Effectiveness Results from the Pilot Phase of a Pragmatic Open-Label Randomised Trial.” The Lancet 387 (10013): 53–60. Search in Google Scholar

McLellan, J.S., M. Pancera, C. Carrico, J. Gorman, J.P. Julien, R. Khayat, R. Louder, R. Pejchal, M. Sastry, K. Dai, S. O'Dell, N. Patel, S. Shahzad-ul-Hussan, Y. Yang, B. Zhang, T. Zhou, J. Zhu, J.C. Boyington, G.Y. Chuang, D. Diwanji, I. Georgiev, Y.D. Kwon, D. Lee, M.K. Louder, S. Moquin, S.D. Schmidt, Z.Y. Yang, M. Bonsignori, J.A. Crump, S.H. Kapiga, N.E. Sam, B.F. Haynes, D.R. Burton, W.C. Koff, L.M. Walker, S. Phogat, R. Wyatt, J. Orwenyo, L.X. Wang, J. Arthos, C.A. Bewley, J.R. Mascola, G.J. Nabel, W.R. Schief, A.B. Ward, I.A. Wilson, and P.D. Kwong. 2011. “Structure of HIV-1 Gp120 V1/V2 Domain with Broadly Neutralizing Antibody PG9.” Nature 480 (7377): 336–343. Search in Google Scholar

Meier, A.S., and P.B. Gilbert. 2005. “Accuracy and Precision of Estimating Intervention Efficacy When the Timing of Observed Events Differ by Treatment Arm.” Contemporary Clinical Trials 26 (5): 598–610. Search in Google Scholar

Moldt, B., E.G. Rakasz, N. Schultz, P.Y. Chan-Hui, K. Swiderek, K.L. Weisgrau, S.M. Piaskowski, Z. Bergman, D.I. Watkins, P. Poignard, and D.R. Burton. 2012. “Highly Potent HIV-Specific Antibody Neutralization in Vitro Translates into Effective Protection against Mucosal SHIV Challenge in Vivo.” Proceedings of the National Academy of Sciences 109 (46): 18921–18925. Search in Google Scholar

Molina, J.-M., C. Capitant, B. Spire, G. Pialoux, L. Cotte, I. Charreau, C. Tremblay, J-M Le Gall, E. Cua, A. Pasquet, F. Raffi, C. Pintado, C. Chidiac, J. Chas, P. Charbonneau, C. Delaugerre, M. Suzan-Monti, B. Loze, J. Fonsart, G. Peytavin, A. Cheret, J. Timsit, G. Girard, N. Lorente, M. Préau, J.F. Rooney, M.A. Wainberg, D. Thompson, W. Rozenbaum, V. Doré, L. Marchand, M-C Simon, N. Etien, J-P Aboulker, L. Meyer, and J-F Delfraissy. 2015. “On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.” New England Journal of Medicine 373 (23): 2237–2246. Search in Google Scholar

Montefiori, D.C. 2014. “Importance of Neutralization Sieve Analyses When Seeking Correlates of HIV-1 Vaccine Efficacy.” Human Vaccines & Immunotherapeutics 10 (8): 2507–2511. Search in Google Scholar

Moore, K.L., and M.J. Van Der Laan. 2009. “Application of Time-To-Event Methods in the Assessment of Safety in Clinical Trials.” U. C. Berkeley Division of Biostatistics Working Paper Series, Paper 248. Search in Google Scholar

NIAID. Daily-Use HIV Prevention Approaches Prove Ineffective among Women in NIH Study. 2013 Last Modified 3/4/2013, Search in Google Scholar

Nishimura, Y., T. Igarashi, N. Haigwood, R. Sadjadpour, R.J. Plishka, A. Buckler-White, R. Shibata, and M.A. Martin. 2002. “Determination of a Statistically Valid Neutralization Titer in Plasma that Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies.” Journal of Virology 76 (5): 2123–2130. Search in Google Scholar

The IMpact-RSV Study Group. 1998. “Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization from Respiratory Syncytial Virus Infection in High-Risk Infants.” Pediatrics 102 (3): 531–537. Search in Google Scholar

Padian, N.S., S.A. Van Der, G. Ramjee, T. Chipato, G. de Bruyn, K. Blanchard, S. Shiboski, E.T. Montgomery, H. Fancher, H. Cheng, M. Rosenblum, M. van der Laan, N. Jewell, and J. Mcintyre. 2007. “Diaphragm and Lubricant Gel for Prevention of HIV Acquisition in Southern African Women: A Randomised Controlled Trial.” Lancet 370 (9583): 251–261. Search in Google Scholar

Patterson, K.B., H.A. Prince, E. Kraft, A.J. Jenkins, N.J. Shaheen, J.F. Rooney, M.S. Cohen, and A.D. Kashuba. 2011. “Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission.” Sci Transl Med 3 (112): 112re4. Search in Google Scholar

Pegu, A., Z.Y. Yang, J.C. Boyington, L. Wu, S.Y. Ko, S.D. Schmidt, K. McKee, W.P. Kong, W. Shi, X. Chen, J.P. Todd, N.L. Letvin, J. Huang, M.C. Nason, J.A. Hoxie, P.D. Kwong, M. Connors, S.S. Rao, J.R. Mascola, and G.J. Nabel. 2014. “Neutralizing Antibodies to HIV-1 Envelope Protect More Effectively in Vivo than Those to the CD4 Receptor.” Science Translational Medicine 6 (243): 243ra88. Search in Google Scholar

Plotkin, S.A., and P.B. Gilbert. 2012. “Nomenclature for Immune Correlates of Protection after Vaccination.” Clinical Infectious Diseases 54 (11): 1615–1617. Search in Google Scholar

Prejean, J., R. Song, A. Hernandez, R. Ziebell, T. Green, F. Walker, L.S. Lin, Q. An, J. Mermin, A. Lansky, and H.I. Hall. 2011. “Estimated HIV Incidence in the United States, 2006-2009.” Plos One 6 (8): 17502. Search in Google Scholar

Qin, L., P.B. Gilbert, D. Follmann, and D. Li. 2008. “Assessing Surrogate Endpoints in Vaccine Trials with Case-Cohort Sampling and the Cox Model.” The Annals of Applied Statistics 2 (1): 386–407. Search in Google Scholar

Rees, H., S. Delany-Moretlwa, C. Lombard, D. Baron, R. Panchia, L. Myer, J. Schwartz, G.F. Doncel, and G. Gray. 2015. FACTS 001 Phase III Trial of Pericoital Tenofovir 1 % Gel for HIV Prevention in Women. Seattle, WA: CROI. Search in Google Scholar

Rida, W., P. Fast, R. Hoff, and T. Fleming. 1997. “Intermediate-Size Trials for the Evaluation of HIV Vaccine Candidates: A Workshop Summary.” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 16 (3): 195–203. Search in Google Scholar

Sather, D.N., J. Armann, L.K. Ching, A. Mavrantoni, G. Sellhorn, Z. Caldwell, X. Yu, B. Wood, S. Self, S. Kalams, and L. Stamatatos. 2009. “Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection.” Journal of Virology 83 (2): 757–769. Search in Google Scholar

Scheid, J.F., H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, T.Y. Oliveira, J. Pietzsch, D. Fenyo, A. Abadir, K. Velinzon, A. Hurley, S. Myung, F. Boulad, P. Poignard, D.R. Burton, F. Pereyra, D.D. Ho, B.D. Walker, M.S. Seaman, P.J. Bjorkman, B.T. Chait, and M.C. Nussenzweig. 2011. “Sequence and Structural Convergence of Broad and Potent HIV Antibodies that Mimic CD4 Binding.” Science 333 (6049): 1633–1637. Search in Google Scholar

Schneider, T.D., and R.M. Stephens. 1990. “Sequence Logos: A New Way to Display Consensus Sequences.” Nucleic Acids Research 18 (20): 6097–6100. Search in Google Scholar

Shibata, R., T. Igarashi, N. Haigwood, A. Buckler-White, R. Ogert, W. Ross, R. Willey, M.W. Cho, and M.A. Martin. 1999. “Neutralizing Antibody Directed against the HIV-1 Envelope Glycoprotein Can Completely Block HIV-1/SIV Chimeric Virus Infections of Macaque Monkeys.” Nature Medicine 5 (2): 204–210. Search in Google Scholar

Shingai, M., O.K. Donau, R.J. Plishka, A. Buckler-White, J.R. Mascola, G.J. Nabel, M.C. Nason, D. Montefiori, B. Moldt, P. Poignard, R. Diskin, P.J. Bjorkman, M.A. Eckhaus, F. Klein, H. Mouquet, J.C. Cetrulo Lorenzi, A. Gazumyan, D.R. Burton, M.C. Nussenzweig, M.A. Martin, and Y. Nishimura. 2014. “Passive Transfer of Modest Titers of Potent and Broadly Neutralizing Anti-Hiv Monoclonal Antibodies Block SHIV Infection in Macaques.” Journal of Experimental Medicine 211 (10): 2061–2074. Search in Google Scholar

Simek, M.D., W. Rida, F.H. Priddy, P. Pung, E. Carrow, D.S. Laufer, J.K. Lehrman, M. Boaz, T. Tarragona-Fiol, G. Miiro, J. Birungi, A. Pozniak, D.A. McPhee, O. Manigart, E. Karita, A. Inwoley, W. Jaoko, J. Dehovitz, L.G. Bekker, P. Pitisuttithum, R. Paris, L.M. Walker, P. Poignard, T. Wrin, P.E. Fast, D.R. Burton, and W.C. Koff. 2009. “Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay Together with an Analytical Selection Algorithm.” Journal of Virology 83 (14): 7337–7348. Search in Google Scholar

Stamatatos, L., L. Morris, D.R. Burton, and J.R. Mascola. 2009. “Neutralizing Antibodies Generated during Natural HIV-1 Infection: Good News for an HIV-1 Vaccine?” Nature Medicine 15 (8): 866–870. Search in Google Scholar

Tudor, D., M. Derrien, L. Diomede, A.S. Drillet, M. Houimel, C. Moog, J.M. Reynes, L. Lopalco, and M. Bomsel. 2009. “HIV-1 Gp41-Specific Monoclonal Mucosal Igas Derived from Highly Exposed but Igg-Seronegative Individuals Block HIV-1 Epithelial Transcytosis and Neutralize CD4(+) Cell Infection: An Iga Gene and Functional Analysis.” Mucosal Immunology 2 (5): 412–426. Search in Google Scholar

UNAIDS. “Report on the Global AIDS Epidemic, 2012 Country Progress Reports. 2013 Accessed Februrary 20, 2013; Search in Google Scholar

UNAIDS. The GAP Report. 2014, Search in Google Scholar

Van Damme, L., A. Corneli, K. Ahmed, K. Agot, J. Lombaard, S. Kapiga, M. Malahleha, F. Owino, R. Manongi, J. Onyango, L. Temu, M.C. Monedi, P. Mak'Oketch, M. Makanda, I. Reblin, S.E. Makatu, L. Saylor, H. Kiernan, S. Kirkendale, C. Wong, R. Grant, A. Kashuba, K. Nanda, J. Mandala, K. Fransen, J. Deese, T. Crucitti, T.D. Mastro, and D. Taylor. 2012. “Preexposure Prophylaxis for HIV Infection among African Women.” New England Journal of Medicine 367 (5): 411–422. . Search in Google Scholar

Van Der Laan, M.J., and S. Rose. 2011. Targeted Learning: Causal Inference for Observational and Experimental Data. New York: Springer. Search in Google Scholar

Van Der Straten, A., L. Van Damme, J.E. Haberer, and D.R. Bangsberg. 2012. “Unraveling the Divergent Results of Pre-Exposure Prophylaxis Trials for HIV Prevention.” Aids 26 (7):. F13-F19. Search in Google Scholar

Walker, L.M., and D.R. Burton. 2010. “Rational Antibody-Based HIV-1 Vaccine Design: Current Approaches and Future Directions.” Current Opinion in Immunology 22 (3): 358–366. Search in Google Scholar

Walker, L.M., M. Huber, K.J. Doores, E. Falkowska, R. Pejchal, J.P. Julien, S.K. Wang, A. Ramos, P.Y. Chan-Hui, M. Moyle, J.L. Mitcham, P.W. Hammond, O.A. Olsen, P. Phung, S. Fling, C.H. Wong, S. Phogat, T. Wrin, M.D. Simek, W.C. Koff, I.A. Wilson, D.R. Burton, and P. Poignard. 2011. “Broad Neutralization Coverage of HIV by Multiple Highly Potent Antibodies.” Nature 477 (7365): 466–470. Search in Google Scholar

Walker, L.M., S.K. Phogat, P.Y. Chan-Hui, D. Wagner, P. Phung, J.L. Goss, T. Wrin, M.D. Simek, S. Fling, J.L. Mitcham, J.K. Lehrman, F.H. Priddy, O.A. Olsen, S.M. Frey, P.W. Hammond, S. Kaminsky, T. Zamb, M. Moyle, W.C. Koff, P. Poignard, and D.R. Burton. 2009. “Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target.” Science 326 (5950): 285–289. Search in Google Scholar

Walker, L.M., M.D. Simek, F. Priddy, J.S. Gach, D. Wagner, M.B. Zwick, S.K. Phogat, P. Poignard, and D.R. Burton. 2010. “A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals.” Plos Pathogens 6 (8): 1001028. Search in Google Scholar

WHO. WHO Expands Recommendation on Oral Pre-Exposure Prophylaxis of HIV Infection (Prep). 2015 Policy brief WHO/HIV/2015.48:2. Search in Google Scholar

WHO in partnership with UNICEF and UNAIDS. Global Report on HIV Treatment 2013: Results, Impact and Opportunities. 2013 Last Modified June 2013; Search in Google Scholar

World Medical Association. 2002;Declaration of Helsinki: ethical principles for medical research involving human subjects; Note of Clarification on Paragraph 29. Accessed July 06, 2015. Search in Google Scholar

Wu, X., Z.Y. Yang, Y. Li, C.M. Hogerkorp, W.R. Schief, M.S. Seaman, T. Zhou, S.D. Schmidt, L. Wu, L. Xu, N.S. Longo, K. McKee, S. O'Dell, M.K. Louder, D.L. Wycuff, Y. Feng, M. Nason, N. Doria-Rose, M. Connors, P.D. Kwong, M. Roederer, R.T. Wyatt, G.J. Nabel, and J.R. Mascola. 2010. “Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1.” Science 329 (5993): 856–861. Search in Google Scholar

Zhou, T., I. Georgiev, X. Wu, Z.Y. Yang, K. Dai, A. Finzi, Y.D. Kwon, J.F. Scheid, W. Shi, L. Xu, Y. Yang, J. Zhu, M.C. Nussenzweig, J. Sodroski, L. Shapiro, G.J. Nabel, J.R. Mascola, and P.D. Kwong. 2010. “Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01.” Science 329 (5993): 811–817. Search in Google Scholar

Supplementary Material

The online version of this article offers supplementary material (DOI:

Received: 2016-4-28
Revised: 2017-3-29
Accepted: 2017-4-27
Published Online: 2017-6-6

© 2017 Walter de Gruyter GmbH, Berlin/Boston